Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Frey S, Linder R, Juckel G, Stargardt T. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. European Journal of Health Economics 2014; 15(2): 133-142 Indexing Status Subject indexing assigned by NLM MeSH Adult; Antipsychotic Agents /economics /therapeutic use; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Flupenthixol /analogs & Hospitalization /economics; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Risperidone /economics /therapeutic use; Schizophrenia /drug therapy; derivatives /economics /therapeutic use AccessionNumber 22014020015 Date bibliographic record published 19/11/2014 |